Business
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.
About this update from Azitra Inc
[{"type":"text","content":"BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.","length":329,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"FY 2025 and Recent Business Highlights","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiated Phase 1/2 Trial for ATR-04 program targeting oncology patients with EGFRi-associated rash; presented ATR-04 trial design and update at ASCO 2025","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced positive preclinical data for ATR-01 program, targeting the treatment of ichthyosis vulgaris","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported promising safety data from Phase 1b Trial of ATR12 in Netherton Syndrome","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed financings of $8.5 million through private placements, follow-on financings and utilization of an equity line of credit.","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":467,"olType":false},{"type":"text","content":""2025 was an exciting year for Azitra as we continued our work to revolutionize the treatment of dermatological diseases with our pipeline of first-in-class, engineered products delivered using topical live biotherapeutics," said Francisco Salva, CEO of Azitra. "A key highlight in 2025 was the progress made in our Phase 1/2 trial for ATR-04 targeting oncology patients with EGFRi-associated rash and the d...